Immunovant CTO receives new option and RSU grants
Immunovant, Inc. Chief Technology Officer Jay S. Stout received new equity awards as compensation.
Rhea-AI Filing Summary
Immunovant, Inc. Chief Technology Officer Jay S. Stout received new equity awards as compensation. He was granted stock options for 96,851 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036, and 66,937 restricted stock units (RSUs).
The RSUs vest as to 25% of the shares on April 1, 2027, with the remaining 75% vesting in twelve successive substantially equal quarterly installments, contingent on continued service. The options vest as to 25% on April 1, 2027, with the balance vesting in thirty-six successive substantially equal monthly installments, also subject to continued service. Following these grants, he directly owns 264,571 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 163,788 shares
Grant/Award
2 txns
Insider
Stout Jay S
Role
Chief Technology Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 96,851 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 66,937 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 96,851 contracts (Direct);
Common Stock — 264,571 shares (Direct)
Footnotes (2)
- F1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.
- F2. These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.
Key Figures
Stock options granted: 96,851 options
Option exercise price: $24.61 per share
Option expiration date: April 7, 2036
+3 more
6 metrics
Stock options granted
96,851 options
Grant on April 7, 2026 to CTO Jay S. Stout
Option exercise price
$24.61 per share
Stock Option (right to buy) granted April 7, 2026
Option expiration date
April 7, 2036
Expiration of granted stock options
RSUs granted
66,937 RSUs
Restricted stock units granted April 7, 2026
Initial vesting date
April 1, 2027
25% of RSUs and 25% of options vest
Common shares after grant
264,571 shares
Direct common stock holdings following RSU award
Key Terms
restricted stock units, 2019 Equity Incentive Plan, Stock Option (right to buy), vest, +1 more
5 terms
restricted stock units financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2019 Equity Incentive Plan financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
vest financial
"The RSUs will vest as to 25% of the total shares on April 1, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer as of such date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Immunovant (IMVT) grant to CTO Jay S. Stout?
Immunovant granted Jay S. Stout stock options for 96,851 shares at $24.61 per share and 66,937 restricted stock units. These awards are part of his compensation and vest over time, encouraging long-term alignment with shareholders.
How do Jay S. Stout’s new RSUs from Immunovant (IMVT) vest?
The 66,937 RSUs vest 25% on April 1, 2027, with the remaining 75% vesting in twelve substantially equal quarterly installments. Vesting is contingent on Mr. Stout’s continuous service with Immunovant through each vesting date under the company’s 2019 Equity Incentive Plan.
What are the vesting terms of Jay S. Stout’s Immunovant (IMVT) stock options?
The 96,851 stock options vest 25% on April 1, 2027, with the remaining 75% vesting in thirty-six substantially equal monthly installments. These options, granted under the 2019 Equity Incentive Plan, require continued service through each vesting date and expire on April 7, 2036.
What is the exercise price and expiration date of Immunovant (IMVT) options granted to Jay S. Stout?
The granted options have an exercise price of $24.61 per share and expire on April 7, 2036. Mr. Stout can only benefit from these options if Immunovant’s share price exceeds the exercise price after vesting and before expiration.
Under which plan were Jay S. Stout’s Immunovant (IMVT) equity awards granted?
Both the RSUs and stock options were granted under Immunovant’s 2019 Equity Incentive Plan. This plan is designed to provide equity-based compensation, aligning key employees’ interests with shareholders through time-based vesting linked to continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
